Guggenheim started coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research note issued to investors on Monday morning, The Fly reports. The firm issued a buy rating on the stock.

A number of other analysts have also recently weighed in on DCPH. Canaccord Genuity assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Tuesday, August 7th. They issued a buy rating and a $55.00 price objective for the company. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, September 11th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, June 11th. Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, September 6th. They issued a buy rating and a $53.00 price objective for the company. Finally, B. Riley cut shares of Deciphera Pharmaceuticals from a buy rating to a neutral rating and set a $43.00 price objective for the company. in a research note on Tuesday, June 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $50.10.

Shares of Deciphera Pharmaceuticals stock opened at $34.74 on Monday. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. Deciphera Pharmaceuticals has a 1-year low of $15.15 and a 1-year high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03. research analysts anticipate that Deciphera Pharmaceuticals will post -2.59 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in Deciphera Pharmaceuticals by 316.1% during the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after purchasing an additional 1,982 shares during the last quarter. New York State Common Retirement Fund raised its stake in Deciphera Pharmaceuticals by 37.5% during the 1st quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock valued at $198,000 after purchasing an additional 2,700 shares during the last quarter. Trexquant Investment LP acquired a new position in Deciphera Pharmaceuticals during the 2nd quarter valued at $203,000. Schwab Charles Investment Management Inc. raised its stake in Deciphera Pharmaceuticals by 20.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 33,791 shares of the company’s stock valued at $678,000 after purchasing an additional 5,737 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Deciphera Pharmaceuticals during the 1st quarter valued at $152,000. Hedge funds and other institutional investors own 53.49% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

See Also: Stock Symbols Definition, Examples, Lookup

The Fly

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.